Development of a pre-erythrocytic P. vivax vaccine to prevent clinical relapse
The goal of this project is the development of a vaccine targeting the pre-erythrocytic stages of malaria infection to prevent relapse infection by Plasmodium vivax. Because 80-90% of active blood stage P. vivax infections come from relapse, and not primary infection, a vaccine against relapse infection would significantly impact transmission worldwide.
Countries
Active Dates
01/01/2019 to 12/31/2023
Faculty Involved
Health Topics